ArticleDiscover oncology2025
LTBP2 promotes meningioma progression by enhancing glycolysis via the PI3K/AKT/mTOR/c-Myc signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningiomas are common central nervous system tumors with few available treatment choices. This research investigates the role of LTBP2 in meningioma biology, emphasizing its ability to be a therapeutic goal.
methodsDifferentially expressed genes (DEGs) were recognized from the GSE84263 dataset. Weighted gene co-expression network analysis (WGCNA) revealed correlated gene modules. Hub genes were discovered via an analysis of the protein-protein interaction (PPI) network, with LTBP2 selected for further study. LTBP2 expression was analyzed utilizing Western blotting (WB) and quantitative reverse transcription-polymerase chain reaction in normal human meningeal cells (NHMCs) and meningioma cell lines. Functional assays assessed cell invasion and migration, proliferation, and apoptosis. Glycolysis was assessed through glucose uptake, lactate production, and extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) measurements. WB analysis assessed related protein levels in the PI3K/AKT and mTOR/c-Myc pathways in meningioma cells.
resultsThe analysis identified 492 upregulated and 677 downregulated genes, with the green module significantly correlated. Six overlapping genes showed elevated expression in tumors. LTBP2 was upregulated in meningioma cells. Functional assays showed that LTBP2 knockdown reduced proliferation, invasion, and migration while increasing apoptosis, whereas its overexpression had the opposite effect, enhancing aggressive cellular behaviors. LTBP2 also promoted glycolysis, as shown by increased lactate production, glucose uptake and ECAR, along with decreasd OCR. Mechanistic studies revealed that LTBP2 activated the PI3K/AKT and mTOR/c-Myc signaling pathways, with c-Myc mediating the glycolytic effects of LTBP2. Importantly, c-Myc knockdown reversed the impacts of LTBP2 on cell invasion, proliferation, and apoptosis.
conclusionLTBP2 plays a critical role in meningioma progression by activating the PI3K/AKT and mTOR/c-Myc signaling pathways, highlighting its potential as a biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.